Member Info for Fadec92

I think some are missing that there is a direct competition with the sales of CBD but the facility is now aimed to be more specialized with high value strains of hemp seed to sell to Hemp Producers with the growth potential of the CBD market!

So feed the growth of the market, so long as there is a growing market then Zoetic will feed this, and will create more product per acre based on the N2 feed!

Unless you pay can only receive first page of quoted article! This one is free and talks about the compound (ustekinumab) IL-12/IL-23 inhibitors for Crohn’s disease, which the payed article is referring too that results are due in this but not covered in the payed for article! So this will give a grounding as to what Don Nicholson is referring too “Excellent review from last Nov. Tyk2 is the dark horse in Th17 autoimmune disorders, in my opinion. Keep an eye on cpmds from both @BMS and @NimbusTx“ Article Tweet! “IL-12 and IL-23 are closely related cytokines with important roles in the regulation of tissue #inflammation. This REVIEW examines the immunobiology of IL-12, IL-23 and IL-17 in #IBD and its potential as a therapeutic target” go.nature.com/2ALoaGM Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158482/ Also he’s saying “Th17 autoimmune disorders” Link to what this is! https://www.hindawi.com/journals/iji/2014/651503/

Article Abstract! https://www.nature.com/articles/s41575-018-0084-8

Krone here’s the direct link for this tweet Thankyou!

https://twitter.com/donwnicholson/status/1139899381589716992?s=21

That’s a good post Stoney!

Hi Simon good to hear from you and hope your well too, good to know you’ve meet the director’s, and they do talk a lot of sense about the oil markets and their focused plan of conventional low cost finds, as they say majors have moved into US unconventional leaving conventional oil and gas, they speak well and have a full timeline of drills with the operators with excitement surrounding it which is always good for sp, if the gas comes through then it should certainly upgrade in MC with an NPV $247m, the oil a long shot but while their there appraising the area then why not test the Cadeby Formation for a little extra in costs! :/)

Looks a good business model too with targeting high value conventional oil and gas assets, very economic compared with unconventional assets, payback of operations much quicker, conventional assets harder to find as and usually in traps and faulted formations, but with the looks of the operations it’s being geared up for a commercial find!

****************************/articles/reabold-resources-rbd-industry-experts-interview-with-zak-mir-447d210/

Is SCAP gone or having a day off, hopefully gone if so then good for SP to move up off buys!

TYK2 SDC-1801 + 1802

“SDC-1801 is further advanced and currently demonstrating excellent tolerability with doses up to 30 times the level that gave good responses in efficacy studies; an MTD has yet to be reached.“

“The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas.”

SRA 737

“Sierra has proposed a registration-intent Phase 2 trial as a route to market in anogenital cancers for this exciting prospect, with potential for accelerated approval and payments due to Sareum linked to the achievement of certain milestones. Registration-intent Phase 2 trials represent an efficient approach to accelerate time to market for drugs intended to treat life-threatening diseases where no effective treatment exists.”
 
“Anogenital cancer represents a distinct and substantial market opportunity as there are currently no 2-line therapies approved once chemotherapy becomes ineffective and these patients have a very poor life expectancy. The striking anti-tumour activity reported in the SRA737+Low Dose Gemcitabine (LDG) trial is a notable result, considering the advanced state of the cancers and the extent of previous treatments that patients received.”

“Both Sierra and Sareum believe that SRA737 is competitively positioned as potentially one of the leading clinical assets in its class. In both trials, the treatments were safe and well tolerated, with the majority of adverse events being only mild or moderate. The safety profiles of SRA737 monotherapy and SRA737+LDG were markedly superior to those of recently discontinued molecules from Lilly (prexasertib) and Genentech/Roche (GDC-0575).”

Progressing the Company!

“Additionally, we continue to seek other opportunities to which the Company could add value and grow the business, and our recently expanded Board is instrumental in this search."

Tim will have to say “Only in Class” now for SRA737!

I think it’s just an error on this sites data feed as happens on all other shares pages here also on the London Stock Exchange site it’s not registered as a duplicate as shows the last 5 trades!

https://m.londonstockexchange.com/exchange/mobile/stocks/summary/GB00B02RFS12GBGBXASX1.html?lang=en

Chk1 deal come from nowhere, no leaks and 3 bagged in 4-6 hours!

Sareum's Tim Mitchell looks ahead to critical Phase II data from flagship Chk1 inhibitor

“Keeping the interested party’s informed and when they have sufficient data for their needs then look what a licensing deal can look like”

Also said that

“To Look to license between now or certainly after pre-clinical safety study’s through to in the clinic”

https://www.proactiveinvestors.co.uk/companies/stocktube/12541/sareum-s-tim-mitchell-looks-ahead-to-critical-phase-ii-data-from-flagship-chk1-inhibitor-12541.html

Certainly in the right place with SDC-1801 (Autoimmune) + SDC-1802 (Cancer) and due an update!

JAK Inhibitors, Potential Market Opportunity & Clinical Pipeline Insights 2019.

Market Overview

“Janus kinase inhibitors have come out as one of the latest potential candidate and growth frontier by many of the scientific researchers involved in the research and development of targeted therapies and cancer drugs. The available JAK inhibitors are most highly focusing on the treatment of rare hematological malignancies including myelofibrosis, primary thrombocythemia, and Polycythemia Vera. Moreover, the continuous efforts of the researchers led to the detection of the JAK role in a wide range of solid tumors like lung cancer, prostate cancer, pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, gastrointestinal cancers, etc.“

https://www.optimainsights.org/reports/95-jak-inhibitors-pipeline-insights

This complements your post Stoney, on where size of big deals and where targeted, Cancer and Small Molecules are top, data is taken from the 4th June 2018 - 15 April 2019!

https://twitter.com/syinvesting/status/1136935832173129728?s=21

https://imgur.com/a/oFEHBKp

https://imgur.com/a/bnPRgQA

It should move up when SCAP has finished selling us cheap shares and could have on Friday, tell tomorrow!

Agreed Krone! ATB! :/)

Sen and colleagues showed that treatment of human small cell lung cancer (SCLC) cell lines with inhibitors of the DNA damage response (DDR) components CHK1 and PARP resulted in increased expression of PD-L1 Further, inhibition of either CHK1 or PARP in immunocompetent genetically engineered mouse models (GEMM) of SCLC resulted in increased levels of cytosolic DNA, which activates the cGAS–STING innate immune signaling pathway to induce IRF3 activation and subsequently drive IFNß-mediated increases in PD-L1 expression and T-cell recruitment in SCLC GEMMs Consistent with these findings, treatment with a CHK1 or PARP inhibitor enhanced the efficacy of anti–PD-L1 therapy and resulted in SCLC tumor regression in vivo Together, these findings suggest that combined targeting of DDR proteins and immune checkpoint blockade is a potential therapeutic strategy for patients with SCLC.

http://cancerdiscovery.aacrjournals.org/content/9/5.cover-expansion

SRA737-04 - Combination of SRA737 with Immuno-Oncology Agents

“Sierra presented preclinical data in February providing evidence of biological synergy between SRA737 and immune checkpoint blockade, a breakthrough approach to cancer therapy that blocks the ability of the tumour cell to evade recognition and attack by the immune system. Sierra is investigating the potential of this combination approach, with further preclinical data expected to be presented in the first half of 2019 and is currently designing a clinical study.”

Delivering a STINGing Blow to Small Cell Lung Cancer via Synergistic Inhibition of DNA-Damage Response and Immune-Checkpoint Pathways

Only a few lines and must be the research that shows :-

•10/10 (100%) regressions at the end of treatment (day 21)
• 8/10 (80%) sustained CRs / cures at day 60

Would be handy to read the full text!

Abstract

Summary: Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of the DNA-damage response and the PD-1 axis, resulting in striking tumor regressions in SCLC mouse models.

http://cancerdiscovery.aacrjournals.org/content/9/5/584?iss=5

Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas

At the 2019 American Association for Cancer Research

“preclinical data showing “profound synergy” for the triple combination of the CHK1 inhibitor SRA737 in combination with low-dose gemcitabine (LDG) and anti-PD-L1 immunotherapy in a mouse model of small cell lung cancer (SCLC)”

SCLC Accounts for 15% of all Lung Cancers cases in the US.

Dr Sen reports that this combination with immune checkpoint blockade and DNA damage repair completely regressed tumours in mouse models.

https://ecancer.org/video/7768/efficacy-and-immune-correlates-of-the-sra737-plus-ldg-regimen-in-combination-with-anti-pd-l1-in-an-sclc-model.php

https://www.proactiveinvestors.co.uk/companies/news/217748/sareums-flagship-chk1-inhibitor-shows-serious-lung-cancer-potential-in-mouse-models-217748.html

The twitter post from Sareum highlighting how pleased Tim is and Tim’s Proactive interview, could be pleased not only for the success of SRA737 so that he could progress SDC-1801 (autoimmune diseases) and SDC-1802 (Cancer) into clinical trials!

“psoriasis, rheumatoid arthritis, inflammatory bowel diseases and lupus) and tumour cell proliferation in certain cancers (e.g. T-cell acute lymphoblastic leukaemia and some solid tumours).

https://twitter.com/sareumplc/status/1135570142337937409?s=21